bavariaron Posted - 17 hours ago

$SGMT $VKTX (3 of 3) International Trade Court Issued Final Ruling Viking v. Ascletis November 22, 2024 (ref VK2809) On November 22, 2024, the ITC issued a final ruling in favor of Viking Therapeutics, granting them a seven-year exclusion order (ref VK2809) against Ascletis Pharma (Formerly Gannex). You said you have more? Please share. Bavariaron, MBA VKTX

bavariaron Posted - 17 hours ago

$SGMT $VKTX (2 of 3) Facts of the Case Against Ascletis Pharma: CDA Breach of Contract (CDA = Confidential Disclosure Agreement) BLUF: Airtight case of IP Theft post CDA (2016 & 2019 ref VK2809) https://fingfx.thomsonreuters.com/gfx/legaldocs/gdpzqqgxlvw/IP%20VIKING%20ASCLETIS%20TRADESECRETS.pdf VKTX

bavariaron Posted - 18 hours ago

$SGMT $VKTX (1 of 3) Ascletis Sued by Their Lawyer related to Viking IP infringement Case …and there’s more obit this shady company. https://www.govinfo.gov/content/pkg/USCOURTS-dcd-1_23-cv-03415/pdf/USCOURTS-dcd-1_23-cv-03415-0.pdf VKTX

valueforme Posted - 18 hours ago

$SGMT $VKTX Wow, what a rabbit hole. It turns out that Ascletis was shopping for MASH oral compounds since 2016. Sagimet (3-V Biosiences at that time) ended up signing a licencing agreement with them for FASN inhibitor which we now know as Denifanstat(ASC40 in Ascletis nomenclature) . And Viking opened their data room to Ascletis twice in 2016 and 2019 for their VK2809 (TRβ Agonist) and Ascletis decided to not sign a collaboration. They "just" came up with their own TRβ Agonist ASC41, and now Viking is suing them for stealing trade secrets https://www.courtlistener.com/docket/66688723/viking-therapeuticsinc-v-ascletis-bioscience-co-ltd/ There is even more to this story, but I'll keep this part to myself. The only hint I can give you is that it's not an accident that these 2 specific classes of mash targeting drugs were licensed. Sagimet shareholders - now you do understand why Ascletis CEO is not in the Sagimet board any more, right?

valueforme Posted - 1 day ago

$SGMT Found a dude on LinkedIn who is a clinical research coordinator at Medical University of South Carolina. He very pedantically specifies all projects he is involved in. To my surprise both Sagimet phase 3 trials are mentioned there with Jul 2024 as a start date of the project. We only figured out about these trials names in November. This gives you an idea that preparations are well underway. Some very interesting negotiations are happening behind the closed doors.

valueforme Posted - 1 day ago

$SGMT The strongest board of directors I've ever seen in this market cap category. The most differentiated oral MASH asset with the complimentary MoA to anything else in MASH. Right people were hired, phase 3 design is blessed, CROs are ready. Anything in dermatology and oncology is just a free add-on.

GXD_Texas Posted - 1 day ago

$SGMT tick tock management! LFG!

GXD_Texas Posted - 2 days ago

@smacsJHI @Kingjake26 $PHAT, $SGMT, $RCAT for me. But still holding this bad boy it ain’t done.

Greenblacks Posted - 2 days ago

$SGMT textbook gap closer

aj10invest Posted - 6 days ago

$SGMT but can we get a run before the dilution? It’s only fair…😉

kthart Posted - 6 days ago

$SGMT merck deal yesterday threw a pall over the obesity drug gruppo, in which sgmt is affiliated

DonkeyPuncherDude Posted - 1 week ago

$SGMT Yawn

Greenblacks Posted - 1 week ago

$SGMT here we go

fancystocks Posted - 1 week ago

$SGMT dilution incoming in the next couple weeks imo.

Dark_Horse_Investments Posted - 1 week ago

$SGMT This is an interesting data set. Lets hope funding inside 60-90 days, 1spt patient 90 days after ( 480 on the tally ). this is ok. management seeks the best deal on skittish capital (macro factors at play, tariffs, rates, economic slowdown et al). Finance round will happen gradual cost of capital on the descent will pave the way. TMR let see if FED decides... The next 3-5 year is a golden age for life sciences as technology (ai screening, et cetera ) & lower cost of capital tail winds will fund discovery... With the right moves we will beat the averages & indexes more than twice over every single year. With the right moves we will beat the averages & indexes more than twice over every single year. Welcome collaborations, in life sciences & with some caution in tech ( my focus/experience is centered in life sciences & credit - id like to expand ).

valueforme Posted - 1 week ago

$SGMT George's and David's largest option tranches are priced at 6.36 and 7.15. They are not going to dilute at current levels. George is 63, Dave is 62. Do they really want to run stay on top of running a multi-year long phase 3 trial? No idea, but they hired Thierry to not do a massive dilution deal here. Recall that David said "we have 170M, we need 400M to get to phase 3 outcome". 230M difference. There is a lot of companies with cash out there. I'd take 20 in cash + CVR and call it a day.

valueforme Posted - 1 week ago

$SGMT Just to put things into perspective. It's day 330 for SGMT

Dark_Horse_Investments Posted - 1 week ago

$SGMT @Peterson28 has a point that it will be rocky for a period. @valuerme is absolutely correct on the "icing on the cake" market cap differential ! SGMT, whether @ $4 or $6 is trading @ just or below its cash balance -> as if its science is worth $ Zer0 ... humm not the case, great 2b results, pathway to accelerated approval, and unique MoA. by the way @Peterson28 IBRX is dump of a company, lacks any comparability w/ SGMT. For one 700 million shares, ~$800 million in debt, a thinly relevant product, a balance sheet held w/ duck tape. That is the wrong company to attempt to make your point. I am prepared to be fully allocated in a price range of $4 to $7... Not a market timer but a long term investor on fundamentals. I am prepared to catch the bumpy road to 2026-27 and cash in @ 5-6X my money...

Dark_Horse_Investments Posted - 1 week ago

$SGMT Great post !!! To enrich the thought: the two alternative competitive trends are (1) FGF21 (fibroblast growth factor, engineered hormone to manage metabolism of lipids) and, (2) THR-β (thyroid hormone beta agonist also designed to manage metabolism lipids) both assist in metabolizing lipids after the body has created them - a kin to fat burner (i did not say it is a fat burner). On the other hand, denifanstat from SAGMT is a FASN is an inhibitor, not hormonal, and helps the problem from the root cause regulates/inhibits the production of fat : "PREVENTIVE". This is the ONLY mechanism of action attacking the problem early on. Candidate patients who may have thyroid issues, could benefit from Deni whereas the other therapies may cause problems. Furthermore not only does the phase 2b data is very strong, and management is being very adept and following on an achievable regulatory path but Deni appears to be the most benign in terms of gi side effects of the lot of MASH candidates.

Greenblacks Posted - 1 week ago

$SGMT shorting here

anesthesia_sleep Posted - 1 week ago

$SGMT next leg up consolidating and incoming! “Analysts note that denifanstat's fibrosis benefit appears underappreciated by the market, especially when compared to other late-stage NASH candidates such as FGF21 analogs. The drug's efficacy in reducing progression to cirrhosis and its strong two-step fibrosis response have caught the attention of hepatologists, who recognize its differentiated mechanism in the competitive NASH landscape.” $XBI $SPY $QQQ

rational1 Posted - 1 week ago

@Peterson28 $sgmt I have learnt to sell the news & somehow managed to get the day's high yesterday with my trading shares. Maintain a core holding though as the data is quite robust. That and the Baker Bros & Stevie Cohen have positions.

valueforme Posted - 1 week ago

$SGMT You're absolutely ignoring the huge valuation gap that exists between Sagimet, AKRO and ETNB, 2 pure play MASH players that are less than a year ahead on their phase 3 MASH trials with non-oral FGF-21 molecules. They have no opportunities to apply these molecules elsewhere, unlike FASN than will find its way in acne and maybe in some cancers. The only reason why this valuation gap exists is a cash pile difference. AKRO and ETNB has cash to run phase 3 MASH trials to competion. Sagimet is not. When Sagimet solves this, it should immediately start climbing to the positive EV territory as the molecule is highly differentiated and complimentary with a lot of other MoA

Stocks4thought Posted - 1 week ago

$SGMT looking for $8 NT

Peterson28 Posted - 1 week ago

$SGMT Happy to see my position recovered but this biggest outflow concerns me yesterday when we saw 40% rally. Who was selling?

Peterson28 Posted - 1 week ago

$SGMT One thing you don't like to see if this is a pump to announce an offering at 50% discount to the $6 to raise 100M. IBRX just did one. Got burnt hard there.

Effe839 Posted - 1 week ago

$SGMT @valueforme any news to justify this +%? I suppose there is something which should be announced soon but news has leaked.

valueforme Posted - 1 week ago

$SGMT Who let the dogs out

mark88arg Posted - 1 week ago

$SGMT any chance this go to 10 dollars by year end .¿?¿

ChartLaboratory_com Posted - 1 week ago

📈 $SGMT (Sagimet Biosciences Inc. - Series A) Current Price: $5.73 (+10.62%) 📊 Measured Move: $2.94 → $6.22 → $9.50 💥 Day Trade Strategy: Entry above $6.30, Target: $7.50–$9.50 📉 Swing Trade Strategy: Entry near $5.00, Target: $7.50–$9.50 Chart: https://www.tradingview.com/x/DEF 💥 Join for More Insights: www.patreon.com/chartlab 🎄 Christmas Sale #Biotech #SGMT #Momentum 📈 $QMCO (Quantum Corporation) Current Price: $23.27 (+25.11%) 📊 Measured Move: $1.36 → $25.20 → $49.04 💥 Day Trade Strategy: Entry above $25.50, Target: $30.00–$49.04 📉 Swing Trade Strategy: Entry near $20.00, Target: $30.00–$49.04 Chart: https://www.tradingview.com/x/GHI 💥 Join for More Insights: www.patreon.com/chartlab 🎄 Christmas Sale #TechStocks #QuantumComput